SUMMARY Ninety patients with duodenal ulcer, divided randomly into three groups, were treated continuously for one year with either glycopyrronium, 1-hyoscyamine (as a sustained-release preparation) or inert tablets. Dosage with active tablets was so adjusted that the patient experienced definite but tolerable side-effects. Basal and maximal gastric acid secretion were measured immediately before and one week after cessation of treatment. There was no significant change in the means of these measurements in patients who received placebo or 1-hyoscyamine. In Wales, 1966) it was stated that reduced levels of acid secretion persisted for up to 30 months after the drug had been stopped. This maintained reduction was thought to reflect the course of the underlying disorder rather than a direct effect of the anticholinergic drug.
SUMMARY Ninety patients with duodenal ulcer, divided randomly into three groups, were treated continuously for one year with either glycopyrronium, 1-hyoscyamine (as a sustained-release preparation) or inert tablets. Dosage with active tablets was so adjusted that the patient experienced definite but tolerable side-effects. Basal and maximal gastric acid secretion were measured immediately before and one week after cessation of treatment. There was no significant change in the means of these measurements in patients who received placebo or 1-hyoscyamine. In those given glycopyrronium, mean basal output was significantly increased. Mean maximal acid output in this group fell, but not significantly.
Individual measurements of maximal acid output showed quite marked fluctuations in all groups. It is concluded that spontaneous changes in parietal cell mass may occur in patients with duodenal ulcer, and that prolonged anticholinergic therapy does not reduce parietal cell mass.
Although it is established that gastric acid secretion is reduced for several hours after the administration of a variety of anticholinergic compounds, there is little information on the effect on gastric secretion of prolonged administration of these drugs. It was reported (Kowaleski, 1964 and 1967) that in the rat administration of propantheline bromide for several months led to a marked reduction of acid secretion, as measured 48 hours after the last dose of the drug. However, a recent study (Kaye, Jacobs, Ireson, and Trevett, 1968a) failed to confirm these findings. Posey, Elliott, Aldridge, Turner, and Franklin (1966) , who gave glycopyrronium to dogs four times daily for 11 weeks, found that the secretion of Heidenhain pouches, and the histamine-stimulated secretion of the intact stomach, did not rise to normal until four weeks after drug withdrawal. However, more recent observations by this group (Posey, Elliott, Shewmake, and Posey, 1968) (Hunt and Wales, 1966) it was stated that reduced levels of acid secretion persisted for up to 30 months after the drug had been stopped. This maintained reduction was thought to reflect the course of the underlying disorder rather than a direct effect of the anticholinergic drug.
In this report, we describe our findings in a group of 90 patients with duodenal ulcer who were treated continuously for one year with anticholinergic drugs.
PATIENTS AND METHODS
All patients were male, had a duodenal ulcer recently demonstrated by radiograph, and had had symptoms within six months of the first examination. They were taking part in a trial of long-term anticholinergic therapy, full details of which will be published shortly, and were allocated randomly to one of three groups.
Twenty-eight patients (group A) received glycopyrronium. Tables I and II respectively. There is no significant difference between the three groups in maximal acid output, or basal acid output after the exclusion of one atypical subject (see footnote to Table I ). (Moeller, 1962; Posey, 1962; Abbo Krieger, and Levey, 1962; Sun, 1962) , (Barman and Larson, 1963) , and histan lated (Abbott et On the first point, it may be relevant that the nocturnal duration of action of glycopyrronium, as assessed by nine-stimu-measurement of salivary flow after single doses of hiroder and drugs, is greater than that of 1-hyoscyamine (Kaye lan, 1968b (Kaye lan, ) et al, 1968b . It is also possible, though unproven, been made that the end-organ specificity of the two drugs may histamine-differ, so that glycopyrronium may have a relatively Christian-greater effect on the stomach. In addition, glycopyr968b), and ronium induces changes in parietal cell ultrastructure s of bella-in the dog and rat, an effect which is not produced constituent by atropine, propantheline, or vagotomy (Elliott and asurements Posey, 1967; Posey et al, 1968) . Furthermore, the e relatively reduction in histamine-stimulated acid secretion n durules, after vagotomy in dogs is further augmented by and glyco-glycopyrronium (Posey et al, 1968) . These observarnary am-tions suggest that this drug acts not only by comexceptions, petitionwith acetylcholine at neuroreceptor sites, but took their possibly also at a more peripheral level. They also t produced indicate a difference between the mode of action of e it would glycopyrronium and that of some, at least, of the trity under-other available anticholinergic compounds.
;uppression
The effects of glycopyrronium upon acid secretion, c degree of as observed in this study, are difficult to explain. The Ly not have increase in basal acid output in patients who nd organs. received this drug may be a 'rebound' phenomenon, may have due perhaps to vagal overactivity following removal d secretion of the inhibitory effect. We do not know whether oergel and this increase is sustained, since further measurements of basal acid secretion have not been perfllected for formed on these patients. There was also an increase eriod pro-in mean basal acid output in patients who received cid output, 1-hyoscyamine, from6.70to 8.28, though this change does not reach statistical significance (0K1 < p < 02).
Quite marked fluctuations in maximal acid output occurred in patients from all three groups. The data of Kay (1953) , Sircus (1960) , and Marks (1961) indicate that changes of up to ± 10% in maximal acid output may result from errors in the method itself. Table VI shows the numbers of patients from each group in whom changes exceeded these arbitrary limits, and illustrates the greater variability of changes in group A. Approximately equal numbers from each group showed an increase greater than 10%. A decrease occurred in rather more patients from group A (glycopyrronium) though this difference between the groups may be due to chance. 'Expressed as percentage differences between first and second measurements. X2 (4 DF) = 6-42; 0 1 < p < 0-2.
Little is known about the possibility that spontaneous fluctuations of parietal cell mass may occur as part of the natural history of duodenal ulcer. These results strongly support this possibility since parietal cell mass correlates closely with histaminestimulated maximal acid output (Card and Marks, 1960) and this with pentagastrin-stimulated maximal acid output (Multicentre pilot study, 1967). Finally, while the parietal cell mass can be artificially increased by such methods as repeated histamine injection (Marks, 1957; Ritchie, Delaney, Barzilai, Lande, and Wangensteen, 1966) or partial duodenal obstruction (Crean, 1967) there is as yet no reliable means whereby the parietal cell mass may be experimentally reduced, with the possible exception of immunological techniques (Walder, 1968) . It would appear from this study that the prolonged and continuous suppression of function which results from long-term administration of potent anticholinergic drugs does not cause a reduction in parietal cell mass.
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